MX2009005692A - Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada. - Google Patents

Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada.

Info

Publication number
MX2009005692A
MX2009005692A MX2009005692A MX2009005692A MX2009005692A MX 2009005692 A MX2009005692 A MX 2009005692A MX 2009005692 A MX2009005692 A MX 2009005692A MX 2009005692 A MX2009005692 A MX 2009005692A MX 2009005692 A MX2009005692 A MX 2009005692A
Authority
MX
Mexico
Prior art keywords
fgf receptor
fusions
biological activity
modified soluble
improved biological
Prior art date
Application number
MX2009005692A
Other languages
English (en)
Spanish (es)
Inventor
Francis Blanche
Beatrice Cameron
Mark Nesbit
Celine Nicolazzi
Sylvie Sordello
Marc Trombe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centelion filed Critical Centelion
Publication of MX2009005692A publication Critical patent/MX2009005692A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009005692A 2006-11-28 2007-11-28 Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada. MX2009005692A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (1)

Publication Number Publication Date
MX2009005692A true MX2009005692A (es) 2009-10-12

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005692A MX2009005692A (es) 2006-11-28 2007-11-28 Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada.

Country Status (33)

Country Link
US (3) US8119770B2 (cg-RX-API-DMAC7.html)
EP (1) EP2092069B2 (cg-RX-API-DMAC7.html)
JP (1) JP2010510801A (cg-RX-API-DMAC7.html)
KR (1) KR20090102769A (cg-RX-API-DMAC7.html)
AR (1) AR063975A1 (cg-RX-API-DMAC7.html)
AT (1) ATE509106T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007326985C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719290A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668932A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003411A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190564A2 (cg-RX-API-DMAC7.html)
CR (1) CR10777A (cg-RX-API-DMAC7.html)
CY (1) CY1112435T1 (cg-RX-API-DMAC7.html)
DK (1) DK2092069T3 (cg-RX-API-DMAC7.html)
EA (1) EA018700B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099361A (cg-RX-API-DMAC7.html)
GT (1) GT200900137A (cg-RX-API-DMAC7.html)
HR (1) HRP20110503T1 (cg-RX-API-DMAC7.html)
IL (1) IL198480A0 (cg-RX-API-DMAC7.html)
MA (1) MA31143B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009005692A (cg-RX-API-DMAC7.html)
MY (1) MY145914A (cg-RX-API-DMAC7.html)
NI (1) NI200900097A (cg-RX-API-DMAC7.html)
NO (1) NO20092414L (cg-RX-API-DMAC7.html)
PE (1) PE20081250A1 (cg-RX-API-DMAC7.html)
PL (1) PL2092069T3 (cg-RX-API-DMAC7.html)
PT (1) PT2092069E (cg-RX-API-DMAC7.html)
RS (1) RS51911B (cg-RX-API-DMAC7.html)
SI (1) SI2092069T1 (cg-RX-API-DMAC7.html)
SV (1) SV2009003272A (cg-RX-API-DMAC7.html)
TN (1) TN2009000184A1 (cg-RX-API-DMAC7.html)
TW (1) TW200839012A (cg-RX-API-DMAC7.html)
WO (1) WO2008065543A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
ES2600631T3 (es) * 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
CN103347514B (zh) * 2010-11-15 2017-02-08 戊瑞治疗有限公司 Fgfr1胞外域组合疗法
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
UY33833A (es) 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
TW201326201A (zh) 2011-11-14 2013-07-01 Five Prime Therapeutics Inc 治療癌症之方法
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
AU2014268519A1 (en) * 2013-05-23 2015-11-05 Five Prime Therapeutics, Inc. Methods of treating cancer
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2019106592A2 (en) * 2017-11-30 2019-06-06 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
BR112020013420A2 (pt) * 2018-01-26 2020-12-01 Genentech, Inc. composições, métodos para tratar doença, para inibir infecção, para tratar lesão, para acelerar ou aprimorar cura, para prevenir ou tratar uma afecção, para tratar síndrome, para tratar endotoxemia, para produzir uma composição, para selecionar um lote, para controlar o teor de ácido e uso
CN113939534B (zh) 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
AU638734B2 (en) * 1989-07-06 1993-07-08 Regents Of The University Of California, The Receptors for fibroblast growth factors
WO1991017183A1 (en) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
CA2086425C (en) 1990-07-06 2006-01-17 Craig A. Dionne Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
EP3263702A1 (en) * 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040259150A1 (en) * 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005016966A2 (en) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
WO2005035741A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ゲノムが改変された細胞
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
CA2565961A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
CA2614039C (en) * 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Also Published As

Publication number Publication date
WO2008065543A3 (en) 2008-08-14
AU2007326985C1 (en) 2014-02-20
US20120195851A1 (en) 2012-08-02
PL2092069T3 (pl) 2011-10-31
EA200970515A1 (ru) 2009-12-30
NO20092414L (no) 2009-08-21
CO6190564A2 (es) 2010-08-19
EA018700B1 (ru) 2013-10-30
MA31143B1 (fr) 2010-02-01
IL198480A0 (en) 2011-08-01
AU2007326985A1 (en) 2008-06-05
SV2009003272A (es) 2010-02-05
EP2092069B2 (en) 2013-12-18
PE20081250A1 (es) 2008-10-07
EP2092069A2 (en) 2009-08-26
PT2092069E (pt) 2011-07-29
CA2668932A1 (en) 2008-06-05
CL2007003411A1 (es) 2008-07-04
CY1112435T1 (el) 2015-12-09
DK2092069T3 (da) 2011-08-29
AR063975A1 (es) 2009-03-04
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
ATE509106T1 (de) 2011-05-15
ECSP099361A (es) 2009-06-30
BRPI0719290A2 (pt) 2014-02-25
HRP20110503T1 (hr) 2011-08-31
MY145914A (en) 2012-05-15
US8119770B2 (en) 2012-02-21
EP2092069B1 (en) 2011-05-11
GT200900137A (es) 2011-09-02
NI200900097A (es) 2010-01-26
US20100061979A1 (en) 2010-03-11
WO2008065543A2 (en) 2008-06-05
TW200839012A (en) 2008-10-01
KR20090102769A (ko) 2009-09-30
AU2007326985B2 (en) 2013-08-15
JP2010510801A (ja) 2010-04-08
US8481487B2 (en) 2013-07-09
CR10777A (es) 2009-07-23
RS51911B (sr) 2012-02-29
SI2092069T1 (sl) 2011-09-30

Similar Documents

Publication Publication Date Title
TN2009000184A1 (en) Modified soluble fgf receptor fc fusions with improved biological activity
WO2011091078A3 (en) Antibody fc variants with enhanced complement activity
MX2013007392A (es) Anticuerpo modificado con vida media mejorada.
WO2007146139A3 (en) Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
WO2008147143A3 (en) Immunoglobulin fusion proteins
WO2005089224A3 (en) iRNA AGENTS TARGETING VEGF
WO2008146911A1 (ja) IL13Ra2に対する抗体およびこれを含む診断・治療薬
GB2455449A (en) Activatable binding polypeptides and methods of indentifcation and use thereof
WO2006116260A3 (en) Modulation of antibody effector function by hinge domain engineering
EP1824872A4 (en) RNAI MODULATION OF MLL-AF4 AND USES THEREOF
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2009001840A1 (ja) ADCC活性又はCDC活性を有する抗Prominin-1抗体
NZ591471A (en) Antibodies to ccr2
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
MX2012003939A (es) Fusiones y conjugados de farmaco.
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2005087810A3 (en) Dimeric fusion proteins and materials and methods for producing them
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
MX2022016407A (es) Anticuerpo biespecifico y los usos del mismo.
DOP2009000115A (es) Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
ATE498016T1 (de) Transposon-system zur gezielten integration

Legal Events

Date Code Title Description
FG Grant or registration